<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-131552" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Federal Medication Development Regulation</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zhang</surname>
            <given-names>Phillip</given-names>
          </name>
          <aff>Augusta Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Winston</surname>
            <given-names>Nicole R.</given-names>
          </name>
          <aff>Augusta University Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Phillip Zhang declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nicole Winston declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-131552.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>This activity examines the regulatory landscape governing the development of medications in the United States. Overseen by the Food and Drug Administration (FDA), the process mandates a collaborative effort among drug sponsors, clinical researchers, and regulatory authorities. Navigating the drug development pipeline, from initial discovery through rigorous investigation, extensive clinical trials, and ultimate FDA approval, is crucial for ensuring the safety and efficacy of pharmaceuticals before their introduction to the consumer market. By scrutinizing federal medication development regulations, this discussion sheds light on the dynamic interactions between the FDA, drug manufacturers, and clinical researchers, offering comprehensive insights into the complexities of bringing new medications to fruition.</p>
        <p>Participants in this activity will gain a greater understanding of the multifaceted framework that guides the development of medications in the United States. The program delves into the intricacies of coordination among drug sponsors, clinical researchers, and regulatory authorities within the context of federal regulations. Examining the entire drug development process, from initial discovery to FDA approval, this activity illuminates the interplay between the key stakeholders involved. By explaining&#x000a0;the regulatory requirements and expectations, this initiative equips healthcare professionals with the knowledge necessary to navigate the landscape of medication development, fostering a deeper appreciation for the regulatory safeguards that underpin the introduction of new pharmaceuticals to the healthcare market.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;specific laws about FDA regulations for drug development.</p></list-item><list-item><p>Evaluate the new drug application process, including expedited review programs.</p></list-item><list-item><p>Interpret&#x000a0;the intellectual property laws regulating drug development.</p></list-item><list-item><p>Evaluate&#x000a0;the process of regulating the production of generic small-molecule drugs and biologics.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131552&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131552">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-131552.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Before 1906, there were few controls on drug distribution, and products were often inconsistent in strength or poorly labeled.<xref ref-type="bibr" rid="article-131552.r1">[1]</xref>&#x000a0;The Federal Drug Administration (FDA) was formed as part of the Pure Food and Drug Act of 1906, which prohibited misleading drug labeling and created consumer protections for drug safety. The Federal Food, Drug, and Cosmetic Act (FDCA) of 1938 would replace the former act and strengthen the FDA's ability to regulate the medication development process. It required manufacturers to provide proof of safety and adequate information on labels.<xref ref-type="bibr" rid="article-131552.r2">[2]</xref>&#x000a0;</p>
        <p>Numerous amendments were added to the FDCA to modify the regulations and oversight of the FDA. The Durham-Humphrey Amendment was enacted to regulate unsafe medications to be taken without medical supervision, distinguishing between over-the-counter and prescription drugs.<xref ref-type="bibr" rid="article-131552.r3">[3]</xref>&#x000a0;</p>
        <p>In 1961, thalidomide was shown to cause severe congenital disabilities after being marketed in Europe, prompting increased regulations on medication development.<xref ref-type="bibr" rid="article-131552.r4">[4]</xref>&#x000a0;There were also cases of thalidomide-induced congenital disabilities in the US. However, the FDA did not approve the medicine. The passage of the Kefauver-Harris Amendment in 1962 would allow the FDA to require proof that drugs were both safe and effective before approval. This amendment contained provisions for obtaining informed consent for clinical trials and initiated Good Manufacturing Practices (GMP).</p>
      </sec>
      <sec id="article-131552.s3" sec-type="Function">
        <title>Function</title>
        <p>The&#x000a0;FDA approval process requires comprehensive&#x000a0;pre-clinical testing followed by multi-phase clinical trials to ensure safety and efficacy. Discovery is the beginning of medication development involving disease study, molecular models, and high-throughput screening to determine potential new drug molecules. Pre-clinical testing involves <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> experiments using cellular and animal models.</p>
        <p>The submission of an Investigational New Drug (IND) application is required before&#x000a0;the drug is administered to human participants.<xref ref-type="bibr" rid="article-131552.r5">[5]</xref>&#x000a0;Once submitted, the FDA has 30 days to decide if the drug is suitable for human testing. When the FDA approves an IND, human testing can proceed with multi-phase clinical trials, which may last 6 to 7 years and average $48 million per drug.<xref ref-type="bibr" rid="article-131552.r6">[6]</xref>&#x000a0;Fewer than 14% of drug candidates will reach FDA approval during this rigorous process.<xref ref-type="bibr" rid="article-131552.r7">[7]</xref>&#x000a0;Additionally, severe and fatal adverse events must be reported to the FDA Adverse Event Reporting System (FAERS) within 15 days. The FDA can halt clinical trials at any time if an investigational drug causes significant harm to patients. The phases of clinical trials (I to IV) are summarized in Table I.<xref ref-type="bibr" rid="article-131552.r8">[8]</xref></p>
        <table-wrap id="article-131552.table0" position="float" orientation="portrait">
          <table style="width: 899.516px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 23px;">
                <td style="width: 62px; height: 23px;" rowspan="1" colspan="1">Phase I</td>
                <td style="width: 765.516px; height: 23px;" rowspan="1" colspan="1">
<p>Initial testing of fewer than&#x000a0;100&#x000a0;healthy patients to determine the pharmacokinetics, toxicology, and drug safety in humans. Roughly&#x000a0;two-thirds of drugs complete phase I testing and proceed to phase II clinical trials.</p>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 62px; height: 13px;" rowspan="1" colspan="1">Phase II</td>
                <td style="width: 765.516px; height: 13px;" rowspan="1" colspan="1">Comprises of testing dozens to hundreds of patients with the targeted disease to determine&#x000a0;drug&#x000a0;efficacy and adverse effects. Only about one-third of these drugs move on to phase III.</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 62px; height: 13px;" rowspan="1" colspan="1">Phase III</td>
                <td style="width: 765.516px; height: 13px;" rowspan="1" colspan="1">Hundreds to thousands of patients with the targeted disease are tested for drug efficacy and adverse effects. Phase III trials compare treatment using the study drug against a placebo. About half of these drugs will move onto the NDA process.</td>
              </tr>
              <tr style="height: 4px;">
                <td style="width: 62px; height: 4px;" rowspan="1" colspan="1">Phase IV</td>
                <td style="width: 765.516px; height: 4px;" rowspan="1" colspan="1">
<p>Phase IV is considered post-market surveillance of the approved drug on thousands of diseased patients. Annual reports are submitted to the FDA to determine if the drug should still be available.&#x000a0;</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>If drug sponsors&#x000a0;can demonstrate adequate safety and efficacy during clinical trials phases I to III, they may subsequently submit a New Drug Application (NDA) or Biologics License Application (BLA).<xref ref-type="bibr" rid="article-131552.r9">[9]</xref>&#x000a0;If the FDA accepts the quality of clinical trial data, then the NDA or BLA will be approved, and drug manufacturers can begin marketing. One of&#x000a0;many FDA-expedited review programs may shorten the developmental process. These expedited processes are granted for investigational drugs that fill an unmet medical need or represent a substantial increase in efficacy for severe medical conditions.<xref ref-type="bibr" rid="article-131552.r10">[10]</xref>&#x000a0;</p>
        <p>Priority review can be used for an NDA or BLA to decrease the FDA review period and may be combined with other expedited review programs.<xref ref-type="bibr" rid="article-131552.r11">[11]</xref> Fast-track review can be requested for IND applications for drugs that fulfill an unmet medical need. Fast-track review allows drug sponsors to meet with the FDA to advance drug development. Breakthrough therapy review can be requested for drugs with clinical data demonstrating significant improvement over existing drugs. Breakthrough drugs also allow drug sponsors to meet with the FDA and sometimes enable sponsors to avoid components of the standard review process. Accelerated approval is intended for developing drugs with long-term clinical endpoints that may be difficult to measure during clinical trials. Other expedited review programs may also be used alongside accelerated approval.</p>
        <p>The FDA continues to monitor newly approved drugs and biologics for long-term safety. Phase IV clinical trials are used for post-market surveillance involving thousands of participants.<xref ref-type="bibr" rid="article-131552.r8">[8]</xref>&#x000a0;During phase IV, drug sponsors must send periodic reports on safety and tolerability to the FAERS. Additionally, the FDA regulates the use of potentially harmful drugs by requiring manufacturers to use Risk Evaluation and&#x000a0;Mitigation Strategy (REMS) programs. Such programs were formalized by the Food and Drug Administration Amendments Act of 2007 and helped to ensure safe drug use by consumers.<xref ref-type="bibr" rid="article-131552.r12">[12]</xref>&#x000a0;For example, isotretinoin is commonly used for acne treatment but has teratogenic effects if taken while pregnant. Isotretinoin is dispensed by a REMS program called iPLEDGE. The iPLEDGE program mandates that female patients using isotretinoin must use&#x000a0;2 birth control methods, take doctor-administered pregnancy tests, and complete online educational modules to mitigate the risk of bearing children with severe congenital disabilities.<xref ref-type="bibr" rid="article-131552.r13">[13]</xref>&#x000a0;There are currently 61 REMS programs with varying degrees of implementation and effectiveness.<xref ref-type="bibr" rid="article-131552.r14">[14]</xref></p>
        <p>US governing authorities heavily regulate intellectual property. The US Patent and Trademark Office grants drug patents, whereas the FDA sets data exclusivity for new medicines. Exclusivity involves inhibiting the approval of competing drugs for a set period to balance novel drug creation and consumer medication accessibility. The FDA allows 5 years of exclusivity for novel small-molecule drugs and 12 years for biologics.<xref ref-type="bibr" rid="article-131552.r15">[15]</xref>&#x000a0;New clinical uses of existing drugs may be granted 3 years of exclusivity. Under the Best Pharmaceuticals for Children Act, 6 months of exclusivity may be added to existing pediatric drugs. Under the Orphan Drug Act, 7 years of market exclusivity is granted for treating rare diseases.<xref ref-type="bibr" rid="article-131552.r16">[16]</xref></p>
        <p>Following the expiration of patents for name-brand drugs, the FDA regulates the production of generic drugs by requiring the submission of an Abbreviated New Drug Application (ANDA). The FDA approval of an ANDA requires evidence from a manufacturer that their production of a generic small-molecule drug is bioequivalent to the existing name-brand drug.<xref ref-type="bibr" rid="article-131552.r17">[17]</xref>&#x000a0;Generic drug applications are considered abbreviated because the FDA does not require pre-clinical and clinical trials to be performed. Exclusivity for ANDAs may be granted for 180 days during a patent challenge by a generic drug manufacturer and 180 days for competitive generic therapy.</p>
        <p>However, biologics are regulated under different rules and require submission of an abbreviated Biologics License Application (aBLA). Generic biologics, or biosimilars, may differ considerably in molecular structure from the original biologic, unlike generic small-molecule drugs.<xref ref-type="bibr" rid="article-131552.r18">[18]</xref>&#x000a0;Manufacturers must prove that a biosimilar exhibits equivalent safety and efficacy as the name-brand biologic despite having molecular heterogeneity. All manufacturers must adhere to GMP regulations set in place by the FDA to ensure quality and safety during&#x000a0;medication production. Likewise,&#x000a0;Good Clinical Practice (GCP) is the norm for designing, performing, conducting, monitoring, auditing, recording, analyzing, and reporting clinical trials. The goal of GCP is to protect the integrity, confidentiality, and rights of trial participants and to assure the precision of data and documented results.<xref ref-type="bibr" rid="article-131552.r19">[19]</xref></p>
      </sec>
      <sec id="article-131552.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Due to the stringent requirements set by the FDA, some studies have revealed the issue of &#x0201c;drug lag&#x0201d; in the US markets. Particularly in the 1970s, new drugs were often approved and marketed far earlier in European markets than in US markets.<xref ref-type="bibr" rid="article-131552.r20">[20]</xref>&#x000a0;This resulted from increased regulatory standards in the US, which increased the time required to verify drug safety. Therefore, while European&#x000a0;consumers were already using novel medications, US consumers often could not access these drugs.&#x000a0;The duration of clinical trials continues to increase across all phases as&#x000a0;the scope of federal&#x000a0;regulations continues to expand, which may continue to hinder the ability of the FDA to approve medications promptly. However, some evidence suggests that the burden of drug lag has decreased in recent years as federal regulations on the pharmaceutical industry have evolved.<xref ref-type="bibr" rid="article-131552.r21">[21]</xref></p>
        <p>The increasing cost of performing clinical trials creates another significant barrier to approving new drugs. The average price of conducting a clinical trial is nearly $48 million per drug.<xref ref-type="bibr" rid="article-131552.r6">[6]</xref>&#x000a0;One reason for the rising costs of clinical trials includes increasing clinical procedures and administrative staff needed throughout each trial.<xref ref-type="bibr" rid="article-131552.r22">[22]</xref>&#x000a0;Greater disease complexity, increasing comparator drugs, and higher failure risk contribute to the growing costs of clinical trials. The rising costs may adversely affect drug manufacturers, leading to fewer new drugs for consumers and decreased pharmaceutical innovation.</p>
      </sec>
      <sec id="article-131552.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The regulations provided by the FDA have&#x000a0;assured the production of safe and efficacious medications for consumers.&#x000a0;For instance, the Kefauver-Harris Amendment, also known as the "Drug Efficacy Amendment," required&#x000a0;pharmaceutical companies&#x000a0;to show evidence of drug efficacy before approval. The legislation also worked to prevent the rebranding of generic drugs as breakthrough drugs&#x000a0;at&#x000a0;a higher price. As a result of modern drug regulations, physicians and pharmacists can inform patients about adverse effects, safe dosages, and the proven effectiveness of medicines in treating disease. In addition, drug sponsors must monitor adverse drug reactions through the&#x000a0;FAERS to safeguard clinical trial participants and consumers.<xref ref-type="bibr" rid="article-131552.r23">[23]</xref>&#x000a0;Historically, the FDA has stopped drug trials prematurely due to high rates of adverse events in concordance with such reporting systems. Thus, patient safety is the foundation of many laws governing drug development.</p>
        <p>Government oversight of intellectual property laws also has clinical implications. Drug manufacturers are allowed drug data exclusivity for several years, during which the manufacturer can recoup the enormous costs associated with research and clinical trials. Data exclusivity promotes pharmaceutical innovation so that novel drugs are created for consumers.&#x000a0;Privatized drug innovation is balanced&#x000a0;by producing cheaper generic drugs after data exclusivity ends. Clinicians are, therefore, able to prescribe more affordable generic medicines to their patients without compromising drug efficacy.&#x000a0;The regulations for generic drugs&#x000a0;provide significantly better health care to consumers from lower socioeconomic backgrounds.</p>
      </sec>
      <sec id="article-131552.s6" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Federal regulations have evolved to improve consumer safety. As mentioned, the FDA attempts to balance pharmaceutical drug innovation with public access to affordable medicines. The processes involved have implications for physicians and pharmacists prescribing medications. Physicians and pharmacists need to consider the bioequivalence of generic drugs when prescribing and educating patients. Furthermore, health professionals researching novel drugs should know drug development processes and federal regulations. A better understanding of these regulations by physicians and pharmacists alike will enhance the complex drug development process.</p>
      </sec>
      <sec id="article-131552.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=131552&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=131552">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/131552/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=131552">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-131552.s8">
        <title>References</title>
        <ref id="article-131552.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barkan</surname>
                <given-names>ID</given-names>
              </name>
            </person-group>
            <article-title>Industry invites regulation: the passage of the Pure Food and Drug Act of 1906.</article-title>
            <source>Am J Public Health</source>
            <year>1985</year>
            <month>Jan</month>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-26</page-range>
            <pub-id pub-id-type="pmid">3881052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wax</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.</article-title>
            <source>Ann Intern Med</source>
            <year>1995</year>
            <month>Mar</month>
            <day>15</day>
            <volume>122</volume>
            <issue>6</issue>
            <fpage>456</fpage>
            <page-range>456-61</page-range>
            <pub-id pub-id-type="pmid">7856995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swann</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>FDA and the practice of pharmacy: prescription drug regulation before the Durham-Humphrey Amendment of 1951.</article-title>
            <source>Pharm Hist</source>
            <year>1994</year>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>55</fpage>
            <page-range>55-70</page-range>
            <pub-id pub-id-type="pmid">11613485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greene</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Podolsky</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Reform, regulation, and pharmaceuticals--the Kefauver-Harris Amendments at 50.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Oct</month>
            <day>18</day>
            <volume>367</volume>
            <issue>16</issue>
            <fpage>1481</fpage>
            <page-range>1481-3</page-range>
            <pub-id pub-id-type="pmid">23075174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holbein</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators.</article-title>
            <source>J Investig Med</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>688</fpage>
            <page-range>688-94</page-range>
            <pub-id pub-id-type="pmid">19602987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Heyward</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional study.</article-title>
            <source>BMJ Open</source>
            <year>2020</year>
            <month>Jun</month>
            <day>11</day>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>e038863</fpage>
            <pub-id pub-id-type="pmid">32532786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Siah</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Estimation of clinical trial success rates and related parameters.</article-title>
            <source>Biostatistics</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>273</fpage>
            <page-range>273-286</page-range>
            <pub-id pub-id-type="pmid">29394327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Umscheid</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Key concepts of clinical trials: a narrative review.</article-title>
            <source>Postgrad Med</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>123</volume>
            <issue>5</issue>
            <fpage>194</fpage>
            <page-range>194-204</page-range>
            <pub-id pub-id-type="pmid">21904102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hearns-Stewart</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Farley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Connelly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lowy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bugin</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Integrated Review: FDA Modernizes the Review of New Drug Marketing Applications.</article-title>
            <source>Ther Innov Regul Sci</source>
            <year>2021</year>
            <month>May</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>467</fpage>
            <page-range>467-472</page-range>
            <pub-id pub-id-type="pmid">33236259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Darrow</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kesselheim</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016.</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <month>Dec</month>
            <day>05</day>
            <volume>318</volume>
            <issue>21</issue>
            <fpage>2137</fpage>
            <page-range>2137-2138</page-range>
            <pub-id pub-id-type="pmid">29209711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kantor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haga</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine.</article-title>
            <source>J Pers Med</source>
            <year>2021</year>
            <month>Jan</month>
            <day>14</day>
            <volume>11</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33466644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toyserkani</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Huynh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Morrato</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.</article-title>
            <source>Front Public Health</source>
            <year>2020</year>
            <volume>8</volume>
            <fpage>43</fpage>
            <pub-id pub-id-type="pmid">32158741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prevost</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>English</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Isotretinoin: update on controversial issues.</article-title>
            <source>J Pediatr Adolesc Gynecol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>290</fpage>
            <page-range>290-3</page-range>
            <pub-id pub-id-type="pmid">24147278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huynh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Toyserkani</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Morrato</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018).</article-title>
            <source>BMC Health Serv Res</source>
            <year>2021</year>
            <month>Aug</month>
            <day>06</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>779</fpage>
            <pub-id pub-id-type="pmid">34362367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldman</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Lakdawalla</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Malkin</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Romley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Philipson</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial data.</article-title>
            <source>Health Aff (Millwood)</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-90</page-range>
            <pub-id pub-id-type="pmid">21209443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herder</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>What Is the Purpose of the Orphan Drug Act?</article-title>
            <source>PLoS Med</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>e1002191</fpage>
            <pub-id pub-id-type="pmid">28045908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wittayanukorn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schick</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Babiskin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lionberger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions.</article-title>
            <source>Ther Innov Regul Sci</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>54</volume>
            <issue>6</issue>
            <fpage>1372</fpage>
            <page-range>1372-1381</page-range>
            <pub-id pub-id-type="pmid">32495310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rumore</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Randy Vogenberg</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Biosimilars: Still Not Quite Ready for Prime Time.</article-title>
            <source>P T</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>366</fpage>
            <page-range>366-75</page-range>
            <pub-id pub-id-type="pmid">27313434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arango</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chuck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ellenberg</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Foltz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gorman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hinrichs</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McHale</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merchant</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Seltzer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shapley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wild</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Good Clinical Practice Training: Identifying Key Elements and Strategies for Increasing Training Efficiency.</article-title>
            <source>Ther Innov Regul Sci</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>480</fpage>
            <page-range>480-486</page-range>
            <pub-id pub-id-type="pmid">27390628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wardell</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Introduction of new therapeutic drugs in the United States and Great Britain: an international comparison.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1973</year>
            <season>Sep-Oct</season>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>773</fpage>
            <page-range>773-90</page-range>
            <pub-id pub-id-type="pmid">4147119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wileman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Drug lag and key regulatory barriers in the emerging markets.</article-title>
            <source>Perspect Clin Res</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>51</fpage>
            <page-range>51-6</page-range>
            <pub-id pub-id-type="pmid">21829782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sertkaya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beleche</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Key cost drivers of pharmaceutical clinical trials in the United States.</article-title>
            <source>Clin Trials</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-26</page-range>
            <pub-id pub-id-type="pmid">26908540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-131552.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakaeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tamon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kadoyama</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okuno</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Data mining of the public version of the FDA Adverse Event Reporting System.</article-title>
            <source>Int J Med Sci</source>
            <year>2013</year>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>796</fpage>
            <page-range>796-803</page-range>
            <pub-id pub-id-type="pmid">23794943</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
